Back to search
FDAFDA · Food and drugs·Recall number D-1525-2022

TEST CYP/PROP (50:50) 100 MG/100 MG/ML Injectable, 12.6 ML vial, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.

Published September 21, 2022 · Recall initiated: August 26, 2022

Summary

FDA records drug Class II recall D-1525-2022, published September 21, 2022 and initiated August 26, 2022. Recalling firm: Carolina Infusion; Status: Completed; Reported quantity: 1 vial; Lot: Lot: 07052022@1 BUD: 10/08/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Carolina Infusion
Distributor
Nationwide in the USA.
Lot
Lot: 07052022@1 BUD: 10/08/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TEST CYP/PROP (50:50) 100 MG/100 MG/ML Injectable, 12.6 ML vial, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. recalled?

Yes. FDA published recall D-1525-2022 on September 21, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail